
InMode Ltd. Retained Earnings | INMD
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings InMode Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 969 M | 875 M | 693 M | 496 M | 334 M | 169 M | 94 M | 33 M | 10.8 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 969 M | 10.8 M | 408 M |
Quarterly Retained Earnings InMode Ltd.
| 2025-Q4 | 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 969 M | 875 M | 693 M | - | - | - | - | 334 M | - | - | - | 169 M | - | - | - | 94 M | - | - | - | 33 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 969 M | 33 M | 452 M |
Retained Earnings of other stocks in the Medical devices industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GBS
GBS
|
-75 M | - | -0.57 % | $ 7.12 M | ||
|
Second Sight Medical Products
EYES
|
-149 M | - | -0.97 % | $ 54.4 M | ||
|
EDAP TMS S.A.
EDAP
|
-82.6 M | - | - | $ 162 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-533 M | - | - | $ 1.77 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-185 M | - | -5.86 % | $ 30.6 M | ||
|
Aziyo Biologics
AZYO
|
-176 M | - | 1.37 % | $ 20.5 M | ||
|
Allied Healthcare Products
AHPI
|
-15.7 M | - | 3.58 % | $ 2.21 M | ||
|
BioSig Technologies
BSGM
|
-718 M | - | 37.08 % | $ 85.7 M | ||
|
Cognyte Software Ltd.
CGNT
|
-157 M | $ 8.47 | 0.71 % | $ 618 M | ||
|
ClearPoint Neuro
CLPT
|
-217 M | $ 13.96 | 0.67 % | $ 395 M | ||
|
Apollo Endosurgery
APEN
|
-337 M | - | - | $ 475 M | ||
|
Avinger
AVGR
|
-421 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-380 M | - | - | $ 3.31 B | ||
|
BIOLASE
BIOL
|
-317 M | - | -13.19 % | $ 166 K | ||
|
Soliton, Inc.
SOLY
|
-70.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-56.2 M | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-119 M | - | 0.03 % | $ 1.58 B | ||
|
Conformis
CFMS
|
-581 M | - | - | $ 16.4 M | ||
|
Misonix, Inc.
MSON
|
-39.3 M | - | - | $ 462 M | ||
|
Dynatronics Corporation
DYNT
|
-40.5 M | - | 14.99 % | $ 929 K | ||
|
Cardiovascular Systems
CSII
|
-424 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-303 M | - | -10.19 % | $ 1.99 M | ||
|
Eargo
EAR
|
-514 M | - | - | $ 10.2 M | ||
|
Intersect ENT, Inc.
XENT
|
-303 M | - | - | $ 955 M | ||
|
Invacare Corporation
IVC
|
-78.4 M | - | - | $ 24.7 M | ||
|
Inogen
INGN
|
-176 M | $ 5.42 | 0.18 % | $ 144 M | ||
|
Integer Holdings Corporation
ITGR
|
994 M | $ 126.5 | 0.8 % | $ 4.39 B | ||
|
Neovasc
NVCN
|
-420 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-275 M | $ 22.41 | 1.17 % | $ 526 M | ||
|
Cytosorbents Corporation
CTSO
|
-312 M | $ 0.35 | 0.03 % | $ 21.8 M | ||
|
SmileDirectClub
SDC
|
-382 M | - | -53.45 % | $ 9.71 M | ||
|
Sientra
SIEN
|
-695 M | - | -16.59 % | $ 10.3 M | ||
|
Silk Road Medical, Inc
SILK
|
-399 M | - | - | $ 1.07 B | ||
|
NanoVibronix
NAOV
|
-90.5 M | - | - | $ 1.08 M | ||
|
Surgalign Holdings
SRGA
|
-624 M | - | -32.98 % | $ 1.68 M | ||
|
ShockWave Medical
SWAV
|
110 M | - | - | $ 12.3 B | ||
|
NuVasive
NUVA
|
86.1 M | - | - | $ 2.07 B | ||
|
Natus Medical Incorporated
NTUS
|
84.5 M | - | 1.94 % | $ 1.05 B | ||
|
Nevro Corp.
NVRO
|
-813 M | - | - | $ 217 M | ||
|
LENSAR
LNSR
|
-178 M | $ 8.58 | 4.0 % | $ 103 M | ||
|
ThermoGenesis Holdings
THMO
|
-284 M | - | -25.84 % | $ 171 K | ||
|
Talis Biomedical Corporation
TLIS
|
-540 M | - | 3.55 % | $ 7.96 M | ||
|
Titan Medical
TMDI
|
-254 M | - | -26.32 % | $ 19.6 M | ||
|
LivaNova PLC
LIVN
|
-1.15 B | $ 81.92 | 0.89 % | $ 4.47 B | ||
|
Butterfly Network
BFLY
|
-879 M | $ 7.36 | 0.96 % | $ 1.82 B | ||
|
Vapotherm
VAPO
|
-548 M | - | 6.72 % | $ 34 M | ||
|
Acutus Medical
AFIB
|
-610 M | - | -26.83 % | $ 2.62 M | ||
|
Globus Medical
GMED
|
1.39 B | $ 78.29 | 0.27 % | $ 10.6 B |